156 related articles for article (PubMed ID: 16798723)
1. Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse.
Anan A; Baskin-Bey ES; Isomoto H; Mott JL; Bronk SF; Albrecht JH; Gores GJ
Am J Physiol Gastrointest Liver Physiol; 2006 Oct; 291(4):G709-16. PubMed ID: 16798723
[TBL] [Abstract][Full Text] [Related]
2. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse.
Canbay A; Feldstein A; Baskin-Bey E; Bronk SF; Gores GJ
J Pharmacol Exp Ther; 2004 Mar; 308(3):1191-6. PubMed ID: 14617689
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
Maseda D; Meister S; Neubert K; Herrmann M; Voll RE
Cell Death Differ; 2008 Mar; 15(3):600-12. PubMed ID: 18188168
[TBL] [Abstract][Full Text] [Related]
4. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
5. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
[TBL] [Abstract][Full Text] [Related]
6. The proteasome inhibitor bortezomib inhibits T cell-dependent inflammatory responses.
Yanaba K; Yoshizaki A; Muroi E; Hara T; Ogawa F; Shimizu K; Sato S
J Leukoc Biol; 2010 Jul; 88(1):117-22. PubMed ID: 20418448
[TBL] [Abstract][Full Text] [Related]
7. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
[TBL] [Abstract][Full Text] [Related]
8. Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer.
Mortenson MM; Schlieman MG; Virudachalam S; Lara PN; Gandara DG; Davies AM; Bold RJ
Lung Cancer; 2005 Aug; 49(2):163-70. PubMed ID: 16022909
[TBL] [Abstract][Full Text] [Related]
9. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib.
Fahy BN; Schlieman MG; Mortenson MM; Virudachalam S; Bold RJ
Cancer Chemother Pharmacol; 2005 Jul; 56(1):46-54. PubMed ID: 15791457
[TBL] [Abstract][Full Text] [Related]
10. Biliary intervention aggravates cholestatic liver injury, and induces hepatic inflammation, proliferation and fibrogenesis in BDL mice.
Wen YA; Liu D; Zhou QY; Huang SF; Luo P; Xiang Y; Sun S; Luo D; Dong YF; Zhang LP
Exp Toxicol Pathol; 2011 Mar; 63(3):277-84. PubMed ID: 20149605
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L
Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibition: mechanism of action.
DeMartino GN
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S5-9. PubMed ID: 19791423
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibition induces hepatic stellate cell apoptosis.
Anan A; Baskin-Bey ES; Bronk SF; Werneburg NW; Shah VH; Gores GJ
Hepatology; 2006 Feb; 43(2):335-44. PubMed ID: 16440346
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors.
Chu S; Alexiadis M; Fuller PJ
Reprod Sci; 2009 Apr; 16(4):397-407. PubMed ID: 19087975
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitor bortezomib promotes a rupture-prone plaque phenotype in ApoE-deficient mice.
Van Herck JL; De Meyer GR; Martinet W; Bult H; Vrints CJ; Herman AG
Basic Res Cardiol; 2010 Jan; 105(1):39-50. PubMed ID: 19693627
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.
Subklewe M; Sebelin-Wulf K; Beier C; Lietz A; Mathas S; Dörken B; Pezzutto A
Hum Immunol; 2007 Mar; 68(3):147-55. PubMed ID: 17349869
[TBL] [Abstract][Full Text] [Related]
17. Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases.
Srimatkandada P; Loomis R; Carbone R; Srimatkandada S; Lacy J
Eur J Haematol; 2008 May; 80(5):407-18. PubMed ID: 18221384
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibition promotes functional recovery after peripheral nerve reperfusion injury.
Park JW; Kim KM; Oh KJ; Rhyu IJ; Jang HS
J Trauma; 2009 Mar; 66(3):743-8. PubMed ID: 19276748
[TBL] [Abstract][Full Text] [Related]
19. Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.
Schmidt N; Gonzalez E; Visekruna A; Kühl AA; Loddenkemper C; Mollenkopf H; Kaufmann SH; Steinhoff U; Joeris T
Gut; 2010 Jul; 59(7):896-906. PubMed ID: 20581238
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
Uddin S; Ahmed M; Bavi P; El-Sayed R; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Hussain AR; Al-Kuraya KS
Cancer Res; 2008 May; 68(9):3379-88. PubMed ID: 18451165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
